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OBJECTIVE — Oxidative stress is a major contributing factor in the development of diabetic
nephropathy. Peroxisome proliferator–activated receptor  heterozygous mice and Pro12Ala
polymorphism in PPARG exhibited increased resistance to oxidative stress. Smoking increases
the production of reactive oxygen species, which accelerates oxidative stress under hyperglyce-
mia.TodeterminewhetherthePro12Alapolymorphism,aloneorincombinationwithsmoking,
contributes to the development of diabetic nephropathy, a case-control study was performed in
760 Chinese patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS — Among patients, 532 had diabetic nephrop-
athy with microalbuminuria (n  245) or overt albuminuria (n  287), and 228 did not show
either of these symptoms but had had diabetes for 10 years and were not undergoing antihy-
pertension treatment.
RESULTS — After adjustment for confounders, the Pro/Pro genotype was signiﬁcantly asso-
ciated with diabetic nephropathy (odds ratio 2.30 [95% CI 1.18–4.45], P  0.014); smoking
was also an independent risk factor for diabetic nephropathy (1.99 [1.08–3.68], P  0.029). In
addition, we identiﬁed possible synergistic effects; i.e., the high-risk group (smokers with the
Pro/Pro genotype) showed 4.52 times higher risk (1.78–11.48,P  0.002) of diabetic nephrop-
athy than the low-risk group (nonsmokers with the Pro/Ala genotype) in a multiple logistic
regression analysis controlled for the confounders.
CONCLUSIONS — Our results indicated that the Pro/Pro genotype and smoking were
signiﬁcant independent risk factors for diabetic nephropathy. The possible synergistic effects of
genotype and smoking may aggravate oxidative stress and contribute to the development of
diabetic nephropathy.
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D
iabetic nephropathy is a leading
cause of end-stage renal disease in
developed countries. A recent epi-
demiological study indicated that albu-
minuria was present in 49.6% of Chinese
type 2 diabetic patients aged 30 years
and living in the Shanghai urban area (1).
Although the causes of diabetic nephrop-
athy are not fully understood, the familial
aggregation of the disease and the dispro-
portionateprevalenceamongspeciﬁceth-
nic minority groups suggest that genetic
factors may inﬂuence the risk of develop-
ing the disease (2). The PPARG gene lo-
cated on chromosome 3 has been linked
to the risk of developing diabetic ne-
phropathy. The peroxisome proliferator–
activated receptor (PPAR)-2i sa
transcription factor formed by an alterna-
tive mRNA splicing pathway, and it regu-
lates the transcription and expression of
numerous target genes, which have been
shown to be involved in adipocyte differ-
entiation, lipid and glucose metabolism,
and atherosclerosis (3). The Pro12Ala
polymorphism, a Pro-to-Ala exchange
that results in the substitution of proline
with alanine at codon 12, was associated
withreductionsinbothDNAbindingand
transcriptionalactivityinvitro,andAla12
carriers showed signiﬁcant improvement
in insulin sensitivity (4). This beneﬁcial
effect of lower PPAR- activity on insulin
sensitivity in humans can be replicated in
PPAR- heterozygous (PPAR-
/) mice
(5).ThePro12Alapolymorphismhasalso
been associated with diabetic nephropa-
thy in Caucasians (6–8). Recent studies
have indicated that the Ala12 allele–
mediated improvement in insulin sensi-
tivity may involve enhanced suppression
of lipid oxidation, which permits more
efﬁcientglucosedisposal(9).Moreover,
adipose tissue–speciﬁc PPAR-2 het-
erozygous mice and human Ala12 allele
carriers show increased resistance to oxi-
dative stress (9,10). Oxidative stress re-
sulting from overproduction of reactive
oxygen species (ROS) under hypergly-
cemic conditions has been suggested to
contribute to the development and pro-
gression of diabetic nephropathy (11).
SmokingincreasestheproductionofROS
(12), consequently accelerating oxidative
stress under hyperglycemic conditions.
Smoking is also known to increase uri-
nary albumin excretion and is predicted
to lead to faster progression of nephropa-
thy in patients with type 2 diabetes (13).
Anumberofepidemiologicalstudieshave
provided evidence that interactions be-
tween genetic and nongenetic risk deter-
minants contribute to the development
and progression of diabetic nephropathy
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shown that the prevalence of Pro12Ala
variesgreatlyamongpopulations,andthe
prevalence in Asians is much lower than
that in Caucasians (15). In addition, the
Pro12Ala polymorphism was found to be
associated with type 2 diabetes in Cauca-
sians, but not in Chinese (16,17). In this
study,weinvestigatedtheinﬂuenceofthe
PPARG Pro12Ala polymorphism on the
risk of diabetic nephropathy and deter-
mined whether this polymorphism and
smoking showed a synergistic effect on
the development of type 2 diabetic ne-
phropathy in Chinese patients.
RESEARCH DESIGN AND
METHODS— We selected type 2 dia-
betic subjects (n  760) of Chinese Han
ethnicity who were inpatients at the De-
partment of Endocrinology and Metabo-
lism and the Department of Nephrology
at Shanghai Jiaotong University Afﬁliated
Sixth People’s Hospital between January
2005 and October 2008. Type 2 diabetes
was diagnosed according to the 2003
AmericanDiabetesAssociationdiagnostic
criteria for diabetes, and subjects were di-
vided into no diabetic nephropathy and
diabetic nephropathy groups according
to their 24-h albumin excretion rates
(AERs). The no diabetic nephropathy
group (n  228) consisted of patients
whohadhadtype2diabetesforatleast10
years, were not receiving antihyperten-
sion treatment, and did not show albu-
minuria (AER 30 mg/24 h). After ruling
outurinarytractinfection,hematuria,ne-
phritis, and other conditions (18), the di-
abetic nephropathy group was further
subdivided into a microalbuminuria
group (n  245, 300 mg/24 h  AER 
30 mg/24 h), and an overt albuminuria
group (n  287, AER 300 mg/24 h),
with AER determined in at least two
consecutive overnight samples col-
lected over a 3- to 6-month period. Di-
abetic retinopathy was evaluated for all
patients simultaneously by an experi-
enced ophthalmologist. In the diabetic
nephropathy microalbuminuria group,
all of the patients were conﬁrmed to have
coexistent diabetic retinopathy.
All of the patients underwent a stan-
dardized clinical and laboratory evalua-
tion. Homeostasis model assessment of
insulin resistance (HOMA-IR) and ho-
meostasis model assessment of -cell
function (HOMA-) were calculated by
using the formulae described by Mat-
thewsetal.(19).Informationonsmoking
habitswasobtainedusingquestionnaires.
Patients who had smoked at least 1 ciga-
rette/day for at least 1 year at the time of
study recruitment were stratiﬁed into the
smoking group, and patients who did not
smoke or had given up smoking for 1
yearatthetimeofstudyrecruitmentwere
stratiﬁed into the nonsmoking group.
This study was approved by the institu-
tional review board of Shanghai Jiaotong
UniversityAfﬁliatedSixthPeople’sHospi-
tal. Written informed consent was ob-
tained from all of the participants.
Genotyping
GenomicDNAwasextractedfrom5mlof
peripheral blood by using the conven-
tional phenol/chloroform method. Mis-
match PCR and restriction fragment-
lengthpolymorphismforHaeIIIdigestion
were used for genotyping analysis of the
Pro12Ala polymorphism by using previ-
ously established procedures (20). For
the genotyping analysis, PCR products
with a length of 155 bp were digested to
two fragments with sizes of 132 and 23
bp, which were for the Pro12 allele, and
thecomplete155-bpfragmentwasforthe
Ala12 allele. To conﬁrm that detection of
thisC3Gnucleotidesubstitution,which
resulted in Pro12Ala (CCA3GCA) by
PCR-restriction fragment-length poly-
morphism analysis, is reproducible, we
performed PCR-based direct sequencing
analysis for each study subject.
Statistical analysis
Because there were no differences be-
tweenthegenotypefrequenciesofthemi-
croalbuminuria and overt albuminuria
groups, we combined these two groups
intoadiabeticnephropathygroupforfur-
ther data analyses. The clinical and labo-
ratory values are expressed as means 
SD or as medians (interquartile range).
Comparisons of the clinical and labora-
tory parameters between the diabetes
with and without diabetic nephropathy
groups as well as those between the geno-
typic groups were performed with un-
paired Student t tests and 	
2 analysis, as
appropriate. Skewed distribution data
such as those for the duration of diabetes,
fasting plasma insulin level, HOMA-,
HOMA-IR, triglyceride level, AER, and
serum creatinine level were logarithmi-
cally transformed before analysis and are
presented as medians (interquartile
range). P  0.05 was considered signiﬁ-
cant. To evaluate the independent contri-
butions of the Pro12Ala polymorphism
and smoking to the risk of diabetic ne-
phropathy,weperformedmultivariatelo-
gisticregressionanalysisoftype2diabetic
patients with diabetic nephropathy (mi-
croalbuminuria and overt albuminuria
grouped together) by using type 2 dia-
betic patients without diabetic nephropa-
thy as the control subjects; the analyses
included possible confounders (sex, age
at diagnosis of diabetes, diabetes dura-
tion,hypertension,triglyceridelevel,total
cholesterol level, and A1C). Odds ratios
(ORs) and 95% CIs were calculated. SPSS
(version 10.0; SPSS, Chicago, IL) was
used for data analysis and processing.
We used SAS (version 9.1.3; SAS In-
stitute, Cary, NC) to calculate sample size
and power. Results of the pilot study,
which enrolled 94 no diabetic nephropa-
thy and 165 diabetic nephropathy pa-
tients, on association between Pro12Ala
and diabetic nephropathy showed that
the OR of the high-risk genotype Pro/Pro
to the low-risk genotype Pro/Ala was
2.21. Thus, we decided to use an OR of
2.0 to calculate sample size. Other as-
sumptions used to calculate sample size
were that 1) the prevalence of the high-
risk genotype of PPARG was 85%, 2) the
sample size proportion between the no
diabetic nephropathy and diabetic ne-
phropathy groups was 1:2, and 3) the
powerwas80%(
0.05);therefore,the
total sample size needed was 732. In our
study, 760 patients including 228 pa-
tients without diabetic nephropathy and
532 patients with diabetic nephropathy
were enrolled. With use of the current
sample, the power to ﬁnd an OR of 2.2
was 82.2% (
0.05); therefore, the
sample size was considered to be
adequate.
To investigate the possible combined
effects of the genotype and smoking on
the risk of diabetic nephropathy, we used
multivariate logistic regression analysis
with stratiﬁcation on the basis of geno-
type (Pro/Pro or Pro/Ala) and smoking
status (smokers or nonsmokers). A low-
risk genotype and no history of smoking
were considered as reference groups. If
thecombinedeffectofthetwofactorsis0,
then there is no sign of interaction be-
tween the factors; consequently, there is
nodeparturefromadditivity.Weusedthe
following formula to calculate the com-
bined effect: 1 ORAB  ORAB 
ORAB, where 1 is the effect of the ref-
erence (21).
RESULTS— In comparison with the
patients without diabetic nephropathy,
the patients with diabetic nephropathy
showed signiﬁcant differences in several
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this study (Table 1). The crude analysis
revealed that the risk of developing dia-
betic nephropathy was signiﬁcantly in-
creased by smoking (OR 2.18 [95% CI
1.30–3.68], P  0.003).
As shown in Table 2, with the excep-
tion of the Pro/Ala patients who had a
lower AER level than the Pro/Pro patients
(P  0.001), there were no differences
between the Ala12 carriers and noncarri-
ers with regard to clinical and laboratory
characteristics. All Ala12 carriers were
heterozygotes (Pro12Ala); there were no
Ala/Ala homozygotes in the population
sample studied. The genotypic distribu-
tion of the Pro12Ala polymorphism in
each group was in Hardy-Weinberg equi-
librium (P  0.05) (Fig. 1). However,
because there were no signiﬁcant differ-
ences between the genotype distributions
in the microalbuminuria and overt albu-
minuria groups, we combined these sam-
plesintoadiabeticnephropathygroup,as
described in RESEARCH DESIGN AND METHODS
(Fig. 1). The Pro/Ala genotype and the
Ala12 allelle frequency in the diabetic ne-
phropathy group were clearly lower than
those in the no diabetic nephropathy
group (6.2 vs. 12.7% for the Pro/Ala ge-
notype and 3.1 vs. 6.4% for the Ala allele;
P  0.003 for both of the parameters)
(Fig. 1).
When the risks of microalbuminuria
and overt albuminuria nephropathy were
separately analyzed using multivariate lo-
gistic regression analysis with adjustment
for possible confounders, the Pro/Pro ge-
notype was signiﬁcantly associated with
overt albuminuria nephropathy (OR 2.76
[95% CI 1.22–6.19], P  0.014). There
was a tendency for association with mi-
croalbuminurianephropathythatwasnot
statistically signiﬁcant (1.94 [0.90–
4.14], P  0.089). In unadjusted
analyses,thePro/Progenotypewassignif-
icantly associated with diabetic ne-
phropathy (2.20 [1.30–3.73], P 
0.003) (Fig. 1).
To evaluate the independent contri-
butions of the polymorphism and smok-
ing to the risk of diabetic nephropathy,
multivariatelogisticregressionanalysesof
type 2 diabetic patients with and without
diabetic nephropathy were performed
with the possible confounders. We ob-
tained the following values for the indi-
vidual confounders: sex (OR 0.92 [95%
CI0.62–1.34],P0.649),ageatdiagno-
sis of diabetes (1.02 [1.00–1.04], P 
0.021), diabetes duration (0.91 [0.88–
0.94], P  0.001), hypertension (2.34
[1.56–3.49], P  0.001), triglyceride
level(1.59[1.18–2.14],P0.002),total
cholesterol level [1.10 [0.94–1.29], P 
0.222), A1C (0.97 [0.92–1.03], P 
0.281), and smoking (1.99 [1.08–3.68],
P  0.029); the Pro/Pro genotype signif-
icantly increased the risk of diabetic ne-
phropathy (2.30 [1.18–4.45], P 
0.014).
To study the possible interaction be-
tween the polymorphism and smoking,
we used a variable that stratiﬁed the par-
ticipants according to the genotype and
smoking status in a multivariate logistic
regression analysis that was adjusted for
the confounders. The high-risk group
(smokers with the Pro/Pro genotype) had
a 4.52 times higher risk of diabetic
nephropathy (95% CI 1.78–11.48) than
the low-risk group (nonsmokers with the
Pro/Ala genotype) (P  0.002), and the
departure from additivity was 1.40, indi-
cating a possible synergistic interaction
between genotype and smoking in pa-
tients with diabetic nephropathy (Fig. 2).
Except for the synergistic interaction be-
tween smoking and genotype, no syner-
gistic effects were found between
smoking and other covariates that were
associated with diabetic nephropathy.
CONCLUSIONS — In our study, the
Pro/Pro genotype showed signiﬁcant risk
associations with diabetic nephropathy,
when adjustments were made for other
risk factors. The association with the Pro/
Pro genotype seemed stronger in patients
withovertalbuminurianephropathythan
inthosewithmicroalbuminurianephrop-
athy.Despitealargersample,subdividing
the patients into microalbuminuria and
overt diabetic nephropathy groups will
lead to a greater risk of statistical instabil-
ity, but we cannot exclude the possibility
that what we see is an association with
overtdiabeticnephropathyandthatother
factors, stronger than the polymorphism,
are more important for the progression
from no diabetic nephropathy to
microalbuminuria nephropathy. These
results for Chinese patients are in agree-
ment with the ﬁndings for Caucasian pa-
tients, which were reported by Herrmann
etal.(6),Caramorietal.(7),andPollexet
al. (8), who found that the frequencies of
the Ala12 allele in German, Brazilian, and
Oji-Cree type 2 diabetic patients with di-
abetic nephropathy were lower than the
Table 1—Clinical and laboratory characteristics of type 2 diabetic patients with and without
diabetic nephropathy
Without diabetic
nephropathy
With diabetic
nephropathy P*
n 228 532 —
Age (years) 65.0  9.6 64.1  12.8 0.328
Age at diagnosis of diabetes (years) 49.7  10.4 54.3  13.0 0.001
Sex (male/female) 101/127 281/251 0.033
Diabetes duration (years) 13.0 (11.0–17.8) 10.0 (4.0–15.0) 0.001
Hypertension (%) 129 (56.6) 391 (73.5) 0.001
Systolic blood pressure (mmHg) 138.1  18.9 143.2  20.2 0.001
Diastolic blood pressure (mmHg) 80.5  10.3 82.7  10.5 0.008
Fasting plasma glucose (mmol/l) 9.1  3.9 9.0  3.5 0.802
A1C (%) 9.2  4.2 8.9  2.7 0.437
Fasting plasma insulin (mU/l) 14.7 (9.2–21.0) 14.8 (9.8–22.8) 0.381
HOMA- 63.8 (34.5–118.4) 62.6 (34.1–137.6) 0.653
HOMA-IR 5.3 (3.3–8.2) 5.7 (3.3–8.6) 0.446
Triglyceride level (mmol/l) 1.3 (0.9–1.9) 1.6 (1.1–2.5) 0.001
Total cholesterol level (mmol/l) 4.8  1.2 4.9  1.4 0.125
Retinopathy (%) 98 (43.0) 284 (53.4) 0.008
Serum creatinine (mol/l) 64.0 (55.0–78.0) 84.0 (64.0–129.0) 0.001
Smoking (%) 19 (8.3) 88 (16.5) 0.003
Hypoglycemic treatments
Insulin (%) 111 (48.7) 275 (51.7) 0.467
OHA (%) 63 (27.6) 152 (28.6)
Insulin  OHA (%) 54 (23.7) 105 (19.7)
Data are means  SD, medians (interquartile range), or n (%). Values of HOMA-, HOMA-IR, and fasting
plasma insulin were calculated for no diabetic nephropathy (n  63) and diabetic nephropathy (n  152)
patients, who were not receiving insulin therapy. *P values were obtained by an unpaired Student t test or
	
2 analysis, as appropriate. OHA, oral hypoglycemic agent.
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without diabetic nephropathy.
The Pro12 allele is more common in
theChinesepopulationthaninCaucasian
populations(95vs.88%)(15,17),andwe
observed a stronger signiﬁcant associa-
tion with diabetic nephropathy. How-
ever, the observed stronger genetic
association with diabetic nephropathy
conﬁrms the earlier ﬁndings, and this as-
sociation can be observed across ethnici-
ties, which highlights the importance of
this polymorphism in the development of
diabeticnephropathy.However,previous
studies reported that the Ala12 allele pro-
videdresistancetotype2diabetesinCau-
casians, but not in Chinese, thus
reﬂecting an ethnic genetic heterogeneity
of type 2 diabetes at this locus (16,17).
Smoking was also an independent
riskfactorforthedevelopmentofdiabetic
nephropathy in the crude analyses as well
as in the analyses performed after adjust-
ment for possible confounders. However,
smoking was a weaker risk factor for mi-
croalbuminuria nephropathy (OR 1.70
[95% CI 0.863–3.351], P  0.125) and a
strongerriskfactorformacroalbuminuria
nephropathy (2.36 [1.21–4.59], P 
0.012), supporting the oxidative stress
hypothesis (11).
Inthepresentstudy,weobservedthat
both homozygosity for the Pro12 allele of
the PPARG Pro12Ala polymorphism and
smoking were associated with a signiﬁ-
cant increase in the risk of diabetic ne-
phropathy, even after adjustments for
possible confounders. Moreover, we also
detected a possible synergistic effect of
these two factors on diabetic nephropa-
thy; i.e., the high-risk group (smokers
with the Pro/Pro genotype) showed 4.52
times higher risk of diabetic nephropathy
than the low-risk group (nonsmoking pa-
tientswiththePro/Alagenotype).Thead-
ipose tissue–speciﬁc PPAR-2 Ala12
carriersexhibitincreasedresistancetoox-
idative stress (9), and smoking increases
theproductionofROS(12).Thus,theag-
gravation of oxidative stress under hyper-
glycemic conditions may reﬂect the
possible synergistic effects of the combi-
nation of the Pro/Pro genotype and con-
stant smoking on the development of
diabetic nephropathy.
The present case-control study was
performedusingarelativelylargersample
size than previous studies and was statis-
tically well powered, involving two care-
fully characterized groups of type 2
diabetic patients with and without dia-
betic nephropathy. We identiﬁed two in-
dependent risk factors, i.e., Pro/Pro
genotypeandsmoking,andwefoundthat
these two risk factors showed synergistic
effectsonthedevelopmentofdiabeticne-
phropathy in Chinese type 2 diabetic pa-
tients, supporting the idea that an
interplaybetweengeneticandnongenetic
risk determinants contributes to the de-
velopment and progression of diabetic
nephropathy (14). The interaction be-
tween the genetic risk factor, the PPARG
gene, and the lifestyle-related risk factor,
Figure 1—Genotypic frequencies of the PPARG Pro12Ala polymorphism in type 2 diabetic
patients with and without diabetic nephropathy. no-DN, no diabetic nephropathy; DN, diabetic
nephropathy. f, Pro/Pro;  , Pro/Ala.
Table 2—Clinical and laboratory characteristics of type 2 diabetic patients classiﬁed accord-
ing to their PPARG Pro12Ala genotypes
Pro/Pro Pro/Ala P*
n 698 62 —
Age (years) 64.4  11.6 64.0  12.9 0.842
Age at diagnosis of diabetes (years) 53.1  12.2 51.3  14.3 0.286
Sex (male/female) 355/343 27/35 0.275
Diabetes duration (years) 10.0 (6.0–15.0) 11.0 (8.8–17.0) 0.163
Hypertension (%) 479 (68.6) 41 (66.1) 0.685
Systolic blood pressure (mmHg) 141.9  20.2 139.5  16.0 0.286
Diastolic blood pressure (mmHg) 82.1  10.5 81.5  10.0 0.696
Fasting plasma glucose (mmol/l) 9.0  3.6 9.5  3.8 0.473
A1C (%) 9.0  3.3 8.9  2.3 0.763
Fasting plasma insulin (mU/l) 14.6 (9.2–22.0) 16.8 (12.4–23.5) 0.140
HOMA- 62.5 (33.8–128.0) 72.1 (50.3–189.9) 0.242
HOMA-IR 5.4 (3.2–8.6) 5.9 (3.8–10.4) 0.211
Triglyceride level (mmol/l) 1.2 (0.9–1.6) 1.1 (0.8–1.6) 0.303
Total cholesterol level (mmol/l) 4.9  1.3 5.1  1.4 0.129
Retinopathy (%) 354 (50.7) 28 (45.2) 0.402
AER (mg/24 h) 80.8 (17.8–377.9) 21.4 (5.8–159.3) 0.001
Serum creatinine (mol/l) 76.0 (60.0–105.8) 68.0 (57.0–104.0) 0.515
Smoking (%) 97 (13.9) 10 (16.1) 0.628
Hypoglycemic treatments
Insulin (%) 351 (50.3) 35 (56.5) 0.414
OHA (%) 197 (28.2) 18 (29.0)
Insulin  OHA (%) 150 (21.5) 9 (14.5)
Data are means  SD, medians (interquartile range), or n (%). Values of HOMA-, HOMA-IR, and fasting
plasma insulin were calculated for patients with Pro/Pro (n  197) and patients with Pro/Ala (n  18)
respectively, who were not receiving insulin therapy. *P values were obtained by an unpaired Student t test
or 	
2 analysis, as appropriate. OHA, oral hypoglycemic agent.
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ever, these are preliminary ﬁndings, and
they should be conﬁrmed by studies in
other ethnic groups. This is the ﬁrst
China- or Asia-speciﬁc report on the ef-
fects of the higher prevalence of the
PPARG Pro/Pro genotype and the interac-
tion between this genotype and smoking
in the development of diabetic nephrop-
athy in type 2 diabetic patients. A large
population study in Japanese type 2 dia-
betic patients, which showed that the
prevalence of this genotype in the Japa-
nese patients was similar to that observed
in Chinese patients, did not show any ef-
fectsofthegenotypeondiabeticnephrop-
athy. However, the results of that study
were inﬂuenced by the standard used for
deﬁning diabetic nephropathy, i.e., AER
10 g/ml (22).
The mechanisms by which the
PPARG Pro12Ala polymorphism contrib-
utestodiabeticnephropathyhavestillnot
been clariﬁed. Previous studies have sug-
gested that Ala12 carriers show signiﬁ-
cant improvement in insulin sensitivity
(4); this suggestion implies that non-Ala
carriers, i.e., patients who are homozy-
gous for the Pro12 allele, show increased
insulin resistance, which contributes to
the development of diabetic nephropa-
thy. However, we could not detect the as-
sociationbetweentheAla12alleleandthe
insulin resistance–related clinical param-
eters; this ﬁnding is consistent with the
results of the study by Li et al. (17) on
diabetic Chinese Hans. In addition, the
latest studies indicated that mice that
wereheterozygousfortheadiposetissue–
speciﬁc PPAR-2 and human carriers of
the Ala12 allele showed increased resis-
tance to oxidative stress (9,10). The en-
hanced oxidative stress tolerance is
associated with signiﬁcant upregulation
of antioxidant genes and a signiﬁcant in-
crease in the adipose tissue of FoxO3a, a
transcription factor that is known to reg-
ulate the clearance of ROS (10). The en-
hanced oxidative stress tolerance of the
Ala12carrieralsoimpliesthatthePro/Pro
genotype increases the production of
ROS, which accelerates oxidative stress,
causing an increase in glomerular albu-
min permeability, and the degree of pro-
teinuriacorrelateswiththeprogressionof
glomerulosclerosis and tubulointerstitial
ﬁbrosis (23). Oxidative stress can cause
insulinresistance,whichisaconsequence
as well as a potential cause of diabetic ne-
phropathy (24).
In summary, our results indicated
thatsmokingandthePro/Progenotypeof
the Pro12Ala polymorphism in the
PPARG gene were signiﬁcant indepen-
dent risk factors for diabetic nephropa-
thy. The possible synergistic effects
between the genotype and smoking im-
plied that a positive interaction between
geneticandnongeneticfactorsmayaggra-
vate oxidative stress and contribute to the
development of diabetic nephropathy in
Chinese type 2 diabetic patients.
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